In patients with non-small cell lung carcinoma (NSCLC) who had EGFR T790M mutations that are resistant to both first- and second-generation EGFR-TKIs, it can help achieve a median progression-free survival (PFS) of approximately 10 months (Mok et al., 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.